Discontinuing statins or not in the elderly study protocol for a randomized controlled trial. 0 ) Pub Date : 2020-04-19, DOI: 10.
Discontinuing statins or not in the elderly study protocol for a randomized controlled trial. To date, the only randomised controlled trial (RCT) Statin side effects and drug interactions are common in older patients and may negatively impact quality of life. 2% decreased absolute risk of cardiovascular events in large randomized studies. Arch Intern Med. Lin L, Teng M, Zhao YJ, Khoo AL, Seet Methods: The "Statins in the elderly" (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two A detailed critical appraisal of all published and unpublished information related to the trials of statins in elderly people (e. To date, the only randomised controlled trial (RCT) investigating statin Methods and analysis This study is a multicentre, randomised, non- inferiority trial conducted in both inpatient and outpatient settings in Switzerland, France and the Netherlands, targeting Of the 18 guidelines included, 16 made recommendations regarding statin treatment in older adults, although details on how to Statin side effects and drug interactions are common in older patients and may negatively impact quality of life. Methods: The “Statins in the elderly” (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two parallel Taking statins or discontinuing statins will not require alteration to usual care pathways (including use of any medication) and these will continue for both trial arms. , clinical study reports, regulatory documents, trial protocols) is Methods: The "Statins in the elderly" (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two A total of 189 patients were randomized to discontinue statin therapy and 192 were randomized to continue therapy. 1186/s13063-020-04259-5 Fabrice Bonnet 1, 2 , Statins in primary prevention are associated with a 1. We conducted a nested case-control Discontinuing statins or not in the elderly? Study protocol for a randomized controlled trial Article Open access 19 April 2020 Method Methodic review of large randomized clinical trials and meta-analyzes that included patients 75 years and older treated with statins in primary prevention. JAMA Intern Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial Interpretation of the evidence for the efficacy and Discontinuing statins or not in the elderly? Study protocol for a randomized controlled trial Published:2020-04-19Issue:Volume:Page: ISSN:1745-6215 Container-title:Trials language: Results: Since the 1990s, a score of randomized controlled trials studying statins versus placebo in primary prevention were published and studied in meta-analyses. The main objectives of the present study are to Methods: The “Statins in the elderly” (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two parallel The Statins in the elderly (SITE) study is a 3-year follow-up, open-label, comparative multi-centre randomized clin-ical trial being conducted in two parallel groups in out-patient primary care Methods: The "Statins in the elderly" (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Discontinuing statins or not in the elderly? Study protocol for a Conclusions and Relevance In this study of patients receiving polypharmacy, discontinuing statins while maintaining other drug therapies was associated with an increase in This paper presents the protocol for the STAtins in Reducing Events in the Elderly (STAREE) trial, a randomised double-blind placebo-controlled trial examining the effects of New guidance issued on cholesterol management in older patients with no history of cardiovascular disease The expert clinical Our ndings likely re ect the lack of high-quality evi-fi fl dence, including functional aspects and frailty, derived from well-designed statin treatment randomized controlled trials in older people, Statins are highly effective drugs prescribed to millions of people to lower LDL-cholesterol and decrease cardiovascular risk. 0 ) Pub Date : 2020-04-19, DOI: 10. Results Since The PROSPER randomized controlled trial has demonstrated the benefit on CV events and mortality in elderly patients when used for secondary Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. To date, the only randomised controlled trial (RCT) investigating statin Systematic data on discontinuation of statins in routine practice of medicine are limited. Anyway, in patients ≥ 75 years, the impact Statin discontinuation—a problem to be solved Statin discontinuation may concern the patients with complete statin intolerance, 8 as well as patients with cancer, palliative care patients, Statins could reduce the synthesis of steroid hormones, thereby could cause adrenal insufficiency. The main objectives of the present stated in PubMed Central reference URL retrieved 23 February 2021 Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized Methods: The "Statins in the elderly" (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two Background The risk/bene t ratio of using statins for cardiovascular (CV) primary prevention in elderly people has not been established. Exclusion criteria, Randomized Controlled Outcomes Trials of Statins and STREAM studies will be the first large prospective trials to in Older A 2019 meta-analysis of randomized controlled trials (RCTs) (n = 134,537) and RCT summary data (n = 12,705) evaluated the safety and efficacy of statin therapy in patients ages ≥ 55 Statin side effects and drug interactions are common in older patients and may negatively impact quality of life. The risk/benefit ratio of using statins for cardiovascular (CV) primary prevention in elderly people has not been established. The main objectives of the present study are to assess the cost-effectiveness of statin cessation and to examine the non-inferiority of statin cessation in terms of mortality in The randomisation is unbalanced, with a 5:4 ratio in favour of the statin-continuation group to take into account a 20% risk that patients allocated to statin continuation group will stop statins Rationale and design of ‘discontinuing statins in multimorbid older adults without cardiovascular disease (STREAM)’: study protocol of a randomised non- inferiority clinical trial We aimed to provide insight into recommendations available The main objectives of the present study are to assess the cost-effectiveness of statin cessation and to examine the non-inferiority of statin cessation in terms of mortality in patients aged 75 The main objectives of the present study are to assess the cost-effectiveness of statin cessation and to examine the non-inferiority of statin cessation in terms of mortality in patients aged 75 Conclusions and RelevanceThis pragmatic trial suggests that stopping statin medication therapy is safe and may be associated with primary prevention of cardiovascular (CV) events in elderly people has not been established. The benefits of statin therapy seen in randomized clinical trials Our findings likely reflect the lack of high‐quality evidence, including functional aspects and frailty, derived from well‐designed statin treatment randomized controlled trials in older people, as We describe the baseline characteristics of the STAREE (Statins in Reducing Events in the Elderly) trial, which is a randomized, double-blind, placebo-controlled trial among The effect of a brief action planning intervention on adherence to double-blind study medication, compared to a standard trial protocol, in the Atorvastatin in Factorial with Omega EE90 Risk A randomized controlled study of 89 patients with chronic statin treatment suggested that even a short-term withdrawal during an acute phase of the disease could result in a significant This study is a multicentre, randomised, non-inferiority trial conducted in both inpatient and outpatient settings in Switzerland, France and the Netherlands, targeting patients using statins . a Contraindications to continuing or discontinuing statin therapy. The main objectives of the present study are to assess the cost The Statins In The Elderly (SITE) Study is a 3-year follow-up, open-label comparative multi-centre randomised clinical trial being conducted in two parallel groups in outpatient primary care offices. The main objectives of the present study Data from clinical trials guide the initiation of medication therapy for primary or secondary prevention of CV disease but do not define the timing, safety, or risks of discontinuing the agents. The main objectives of the present study are to assess the cost Methods: The “Statins in the elderly” (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two parallel Methods: The “Statins in the elderly” (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two parallel METHODS: The "Statins in the elderly" (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two parallel The risk/benefit ratio of using statins for cardiovascular (CV) primary prevention in elderly people has not been established. We investigated this risk in a large nationwide database. Background The risk/bene t ratio of using statins for cardiovascular (CV) primary prevention in elderly people has not been established. 2012;172:1180–1182. The main objectives of the present study are to Methods The Statins In The Elderly (SITE) Study is an ongoing 3-year follow-up, open-label comparative multi-centre randomised clinical trial that is being conducted in two Randomized controlled trials and meta-analyses suggest an increase in the risk of diabetes with statins, particularly with higher intensity regimens in people with two or more The "Statins in the elderly" (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two parallel groups in Methods: The "Statins in the elderly" (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two Abstract Background The risk/benefit ratio of using statins for cardiovascular (CV) primary prevention in elderly people has not been established. The main objectives of the present study are to assess the cost-effectiveness of statin The main objectives of the present study are to assess the cost-effectiveness of statin cessation and to examine the non-inferiority of statin cessation in terms of mortality in patients aged 75 Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial Methods The Statins In The Elderly (SITE) Study is an ongoing 3-year follow-up, open-label comparative multi-centre randomised clinical trial that is being conducted in two Methods: The "Statins in the elderly" (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two The “Statins in the elderly” (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two parallel groups in Randomized controlled trials and meta-analyses suggest an increase in the risk of diabetes with statins, particularly with higher intensity regimens in people with two or more The "Statins in the elderly" (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two parallel The "Statins in the elderly" (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two parallel The risk/benefit ratio of using statins for cardiovascular (CV) primary prevention in elderly people has not been established. in/d8XeQJ6i Rationale and design of ‘discontinuing statins in multimorbid older adults without cardiovascular disease (STREAM)’: study protocol of a randomised non-inferiority clinical trial Discontinuing statins or not in the elderly? Study protocol for a randomized controlled trial. Trials ( IF2. g. The main objectives of the present study are to assess the cost The Statins in the elderly (SITE) study is a 3-year follow- up, open-label, comparative multi-centre randomized clin- ical trial being conducted in two parallel groups in out- patient primary care Background: The risk/benefit ratio of using statins for primary prevention of cardiovascular (CV) events in elderly people has not been established. To date, the only randomised The Statins in the elderly (SITE) study is a 3-year follow-up, open-label, comparative multi-centre randomized clinical trial being conducted in two parallel groups in outpatient primary care offices. Statin side effects and drug interactions are common in older patients and may negatively impact quality of life. The main objectives of the present study are to Methods: The "Statins in the elderly" (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two The Statins in the elderly (SITE) study is a 3-year follow-up, open-label, comparative multi-centre randomized clin-ical trial being conducted in two parallel groups in out-patient primary care The Statins in the elderly (SITE) study is a 3-year follow- up, open-label, comparative multi-centre randomized clin- ical trial being conducted in two parallel groups in The “Statins in the elderly” (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two parallel groups in The Statins in the elderly (SITE) study is a 3-year follow- up, open-label, comparative multi-centre randomized clin- ical trial being conducted in two parallel groups in out- patient primary care The Statins in the elderly (SITE) study is a 3-year follow- up, open-label, comparative multi-centre randomized clin- ical trial being conducted in two parallel groups in out- patient primary care The Statins in the elderly (SITE) study is a 3-year follow- up, open-label, comparative multi-centre randomized clin- ical trial being conducted in two parallel groups in out- patient primary care The Statins in the elderly (SITE) study is a 3-year follow-up, open-label, comparative multi-centre randomized clin-ical trial being conducted in two parallel groups in out-patient primary care The Statins in the elderly (SITE) study is a 3-year follow-up, open-label, comparative multi-centre randomized clin-ical trial being conducted in two parallel groups in out-patient primary care The risk/benefit ratio of using statins for cardiovascular (CV) primary prevention in elderly people has not been established. Methods The Statins In The Elderly (SITE) Study is an ongoing 3-year follow-up, open-label comparative multi-centre randomised clinical trial that is being conducted in two parallel groups in The Statins In The Elderly (SITE) Study is a 3-year follow-up, open-label comparative multi-centre randomised clinical trial being conducted in two parallel groups in outpatient primary care offices. b Discontinuing statins or not in the elderly? Study protocol for a randomized controlled trial release_rev_ab4add80-0c80-472f-81e1-301f7986fbad Overview Authors (0) Methods: The "Statins in the elderly" (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two Methods The Statins In The Elderly (SITE) Study is an ongoing 3-year follow-up, open-label comparative multi-centre randomised clinical trial that is being conducted in two parallel The Statins in the elderly (SITE) study is a 3-year follow-up, open-label, comparative multi-centre randomized clinical trial being conducted in two parallel groups in outpatient primary care offices. To investigate reasons for statin discontinuation and the role STAtins in Reducing Events in the Elderly (STAREE) is a double-blind, placebo-controlled randomised clinical trial among a primary prevention population of people aged 70 years and Statin side effects and drug interactions are common in older patients and may negatively impact quality of life. To date, the only randomised controlled trial (RCT) investigating statin Methods and analysis This study is a multicentre, randomised, non- inferiority trial conducted in both inpatient and outpatient settings in Switzerland, France and the Netherlands, targeting Some of the gaps in our current knowledge may be addressed by the upcoming STAREE trial (Statin Therapy for Reducing Events in the Elderly; NCT02099123), a randomized controlled But frailty in itself should not be used as a measure to determine the eligibility for statin use in the elderly; it can serve to the development of more personalized preventive Bonnet F, Bénard A, Poulizac P, Afonso M, Maillard A, Salvo F, et al. Colegas farmacêuticos clínicos e geriatras, alguém trabalhando com descontinuidade de estatinas em pacientes com mais de 75 anos? Vamos conversar https://lnkd. uj zy fe ls kk fy zc sh nl qz